Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024 Meeting
SEATTLE, May 3, 2024 /PRNewswire/ -- Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented during the Immunology 2024 meeting, May 3–7 in Chicago, Illinois.
- SEATTLE, May 3, 2024 /PRNewswire/ -- Mozart Therapeutics , the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells.
- The data will be presented during the Immunology 2024 meeting, May 3–7 in Chicago, Illinois.
- Presentation highlights demonstrate KIR x ICOS Modulator:
Restores and potentiates CD8 Treg function through binding the inhibitory receptor KIR and the costimulatory receptor ICOS, both expressed on CD8 Treg
"Our preclinical data underscore the potential of our KIR x ICOS CD8 Treg Modulator as a selective therapeutic approach for highly inflammatory autoimmune diseases, including Crohn's disease and ulcerative colitis. - Findings show that the Modulator is selective toward CD8 Treg, efficacious in models of disease, and has an encouraging safety profile," said Dr. Kristine Swiderek, Chief Scientific Officer at Mozart Therapeutics.